BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32829076)

  • 1. Alternative biomarkers for classification of latent tuberculosis infection status in pregnant women with borderline Quantiferon plus results.
    Tesfaye F; Sturegård E; Walles J; Winqvist N; Balcha TT; Karlson S; Mulleta D; Isberg PE; Jansson M; Björkman P
    Tuberculosis (Edinb); 2020 Sep; 124():101984. PubMed ID: 32829076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection.
    Petrone L; Vanini V; Chiacchio T; Petruccioli E; Cuzzi G; Schininà V; Palmieri F; Ippolito G; Goletti D
    Tuberculosis (Edinb); 2018 Jul; 111():147-153. PubMed ID: 30029901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting.
    König Walles J; Tesfaye F; Jansson M; Tolera Balcha T; Winqvist N; Kefeni M; Garoma Abeya S; Belachew F; Sturegård E; Björkman P
    PLoS One; 2018; 13(4):e0193589. PubMed ID: 29617458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QuantiFERON-TB Gold Plus combined with HBHA-Induced IFN-γ release assay improves the accuracy of identifying tuberculosis disease status.
    Tang J; Huang Y; Jiang S; Huang F; Ma T; Qi Y; Ma Y
    Tuberculosis (Edinb); 2020 Sep; 124():101966. PubMed ID: 32866942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study.
    Zhang L; Yang Z; Wu F; Ge Q; Zhang Y; Li D; Gao M; Liu X
    BMC Infect Dis; 2024 Jan; 24(1):28. PubMed ID: 38166667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infection.
    Akashi S; Suzukawa M; Takeda K; Asari I; Kawashima M; Ohshima N; Inoue E; Sato R; Shimada M; Suzuki J; Yamane A; Tamura A; Ohta K; Tohma S; Teruya K; Nagai H
    J Infect Chemother; 2021 Apr; 27(4):617-624. PubMed ID: 33317988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.
    Petruccioli E; Vanini V; Chiacchio T; Cuzzi G; Cirillo DM; Palmieri F; Ippolito G; Goletti D
    Tuberculosis (Edinb); 2017 Sep; 106():38-43. PubMed ID: 28802403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Borderline QuantiFERON results and the distinction between specific responses and test variability.
    Uzorka JW; Bossink AWJ; Franken WPJ; Thijsen SFT; Leyten EMS; van Haeften AC; Doornenbal G; Boonstra P; Ottenhoff THM; Arend SM
    Tuberculosis (Edinb); 2018 Jul; 111():102-108. PubMed ID: 30029893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers to identify
    Uzorka JW; Bakker JA; van Meijgaarden KE; Leyten EMS; Delfos NM; Hetem DJ; Kerremans J; Zwarts M; Cozijn S; Ottenhoff THM; Joosten SA; Arend SM
    Eur Respir J; 2022 Aug; 60(2):. PubMed ID: 35058249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CD8 T-cell in immune response to tuberculosis-specific antigen in QuantiFERON-TB Gold Plus.
    Tsuyuzaki M; Igari H; Okada N; Suzuki K
    J Infect Chemother; 2020 Jun; 26(6):570-574. PubMed ID: 32067903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.
    Theel ES; Hilgart H; Breen-Lyles M; McCoy K; Flury R; Breeher LE; Wilson J; Sia IG; Whitaker JA; Clain J; Aksamit TR; Escalante P
    J Clin Microbiol; 2018 Jul; 56(7):. PubMed ID: 29743310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls.
    Wergeland I; Assmus J; Dyrhol-Riise AM
    PLoS One; 2016; 11(9):e0163848. PubMed ID: 27685462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study.
    Alsleben N; Ruhwald M; Rüssmann H; Marx FM; Wahn U; Magdorf K
    Scand J Infect Dis; 2012 Apr; 44(4):256-62. PubMed ID: 22103555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of anti-tuberculous antibiotics and corticosteroids on cytokine production in QuantiFERON-TB Gold In Tube assays.
    Clifford V; Zufferey C; Germano S; Ryan N; Leslie D; Street A; Denholm J; Tebruegge M; Curtis N
    Tuberculosis (Edinb); 2015 May; 95(3):343-9. PubMed ID: 25837441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre verification study of the QuantiFERON
    Pieterman ED; Liqui Lung FG; Verbon A; Bax HI; Ang CW; Berkhout J; Blaauw G; Brandenburg A; van Burgel ND; Claessen A; van Dijk K; Heron M; Hooghiemstra M; Leussenkamp-Hummelink R; van Lochem E; van Loo IHM; Mulder B; Ott A; Pontesilli O; Reuwer A; Rombouts P; Saegeman V; Scholing M; Vainio S; de Steenwinkel JEM
    Tuberculosis (Edinb); 2018 Jan; 108():136-142. PubMed ID: 29523314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease.
    Won EJ; Choi JH; Cho YN; Jin HM; Kee HJ; Park YW; Kwon YS; Kee SJ
    J Infect; 2017 Mar; 74(3):281-293. PubMed ID: 27871809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosis.
    Suzukawa M; Takeda K; Akashi S; Asari I; Kawashima M; Ohshima N; Inoue E; Sato R; Shimada M; Suzuki J; Yamane A; Tamura A; Ohta K; Tohma S; Teruya K; Nagai H
    J Infect; 2020 May; 80(5):547-553. PubMed ID: 32092390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting.
    Wikell A; Jonsson J; Dyrdak R; Henningsson AJ; Eringfält A; Kjerstadius T; Hålldin E; Baqir H; Kholod V; Sturegård E; Bruchfeld J; Schön T
    J Clin Microbiol; 2021 Nov; 59(12):e0137021. PubMed ID: 34550805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study.
    Pérez-Recio S; Pallarès N; Grijota-Camino MD; Sánchez-Montalvá A; Barcia L; Campos-Gutiérrez S; Pomar V; Rabuñal-Rey R; Balcells ME; Gazel D; Montiel N; Vicente D; Goić-Barišić I; Schön T; Paues J; Mareković I; Cacho-Calvo J; Barac A; Goletti D; García-Gasalla M; Barcala JM; Tórtola MT; Anibarro L; Suárez-Toste I; Moga E; Gude-Gonzalez MJ; Naves R; Karslıgil T; Martin-Peñaranda T; Stevanovic G; Trigo M; Rubio V; Karaoğlan İ; Bayram N; Alcaide F; Tebé C; Santin M;
    Microbiol Spectr; 2021 Dec; 9(3):e0097221. PubMed ID: 34756079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host biomarkers other than interferon gamma in QFT-TB supernatants for identifying active tuberculosis.
    Zhou Y; Zhang F; Shi H; Wu P; Zhou Y
    Tuberculosis (Edinb); 2022 Sep; 136():102256. PubMed ID: 36113397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.